STEROID

Steroid Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for steroid-dependent diseases and hormone-sensitive cancers. The company's lead program, ST-002, is a potent and selective small molecule inhibitor of the steroid sulfatase (STS) enzyme, which plays a critical role in the local production of active steroids in diseased tissues. ST-002 is currently being evaluated in Phase 2 clinical trials for the treatment of Cushing's syndrome and is also being explored for oncology indications such as breast and prostate cancer. By targeting the intracrine production of hormones, Steroid Therapeutics aims to provide more effective and better-tolerated treatment options for patients with endocrine and metabolic disorders. The company is headquartered in Chicago and leverages deep expertise in steroid biochemistry to address significant unmet medical needs.